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Abstract The main objective of the clinical development programme for BDP Modulite@, a new non-extra fine 
formulation of beclometasone dipropionate (BDP) in hydrofluoroalkane (HFA), has been to demonstrate therapeutic 
equivalence compared with standard BDP chlorofluorocarbon (CFC) products at the recommended posology (delivered 
dose and patient population).A total of I I58 asthmatic patients were included in five clinical studies and 658 patients were 
treated with BDP Modulite@‘. Four studies were undertaken in mild or moderate-to-severe asthmatic adults, while one 
study was carried out in children.The duration of treatment was I2 weeks in three studies and 6 weeks in the other two 
studies. A range of doses of BDP Modulite@ from 200 pg bid up to I500 pg bid was evaluated against CFC comparators. 
The primary efficacy variable in all studies was morning PEFR while secondary variables included other lung function 
parameters, symptom scores and salbutamol use. All studies demonstrated equivalence of efficacy for morning PEFR for 
BDP Modulite@ versus BDP-CFC when compared on a microgram for microgram basis.The secondary outcome variables 
also consistently support similar efficacy of the two products.The safety and tolerability profile for BDP Modulite@ was 
similar to BDP-CFC; the incidence of adverse events was comparable between treatments and plasma and urinary cortisol 
were generally unchanged in patients receiving IO00 pg day -1 for 6- I2 weeks. In conclusion, the results of the clinical 
studies with BDP Modulite@ show that this new HFA formulation allows a seamless transition to CFC-free BDF: thus 
simplifying the changeover: 
02002 Elsevier hence Ltd 
INTRODUCTION 
Inhaled corticosteroids (ICS) are recommended by all 
guidelines as first-line therapy in the control of persistent 
asthma (I), and are more commonly delivered via 
pressurized aerosols (metered dose inhalers-MDls). 
Beclometasone dipropionate (BDP) was the first 
effective and safe ICS to be marketed (2). It is still largely 
used for the treatment of asthma and chronic obstructive 
pulmonary disease (COPD). 
Chlorofluorocarbons (CFCs) are conventional 
propellants widely used in the delivery of MDls. They 
have been administered to millions of asthmatics and 
COPD patients. They are inexpensive, reliable and 
effective but their use is now strictly limited under the 
Montreal Protocol because of their deleterious effects 
on ozone (3). Before the start of the phase-out of CFCs, 
alternative CFC-free propellants had been developed (4). 
Hydrofluoroalkanes (HFAs) have been developed as 
alternative propellants to CFCs as they do not deplete 
the ozone layer (5). HFA I34a is one HFA that has been 
developed as a replacement propellant for use in MDls 
since it is chemically inert, non-flammable and of low 
toxicity (6-10). In 1994, the European Committee for 
Proprietary Medicinal Products (CPMP) concluded that 
HFA I34a could be a suitable alternative to CFCs used in 
the formulation of medicinal products, including 
pressurized MDls, for treatment of asthma (CPMP, 1993) 
(I I) and this has been borne out by the subsequent 
development of several inhaled asthma medicines 
containing this propellant. 
CFCs and HFAs share a number of basic technical 
characteristics but differ in such physical properties as 
density, vapour pressure, molecular polarity and 
evaporation kinetics.These differences have necessitated 
the development of new formulations, valves and 
manufacturing processes for HFA I34a inhalers. 
As a result of the technical difficulties encountered in 
formulating an HFA l34a BDP product, the aerosols 
produced by currently marketed products (QvarTM, 3M 
and BeclazoneTM, Norton Healthcare) are different to 
the BDP-CFC products (I 2- I4).The size of the particles 
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released from the pressurized aerosol is smaller in order 
to target the lower airways and there appears to be a 
doubling potency of BDP-HFA compared with BDP-CFC 
(I 5,16). This implies that, in the switching phase from 
CFC to BDP-HFA, the dosage must be halved. 
Therefore, in order to minimize disruption to 
prescribers and patients, a new HFA I34a formulation of 
BDP has been developed by Chiesi Farmaceutici with the 
objective of producing solution formulations of BDP- 
HFA l34a in pressurized MDls that are equivalent in 
terms of efficacy, safety and dose per actuation 
performance to the currently marketed BDP-CFC 
containing products.The inclusion of glycerol as a non- 
volatile co-solvent has allowed the particle size of the 
inhaled drug to be rendered as close as possible to that 
of the conventional CFC. It has also been shown that the 
selection of an appropriate actuator orifice diameter 
contributes to the modulation of an aerosol cloud 
allowing the maintenance of an equivalence between the 
dose of HFA and CFC-formulated drugs.This new non- 
extra fine HFA I34a formulation, BDP Modulite@, allows 
a seamless transition to CFC-free BDP minimizing 
difficulties to both prescribers and patients. 
Studies carried out with the BDP Modulite@ 
formulation have been performed according to the 
recommendations of the European Guidelines for the 
phase-out of CFCs in the MDI (I I). 
CLINICALTRIALS WITH NON-EXTRA 
FINE BDP-HFA FORMULATION (BDP 
MODULITEB) 
I. Lefranqois et a/:A new non-ultra fine 
BDP-HFA I34a formulation clinical 
equivalence of efficacy and safety vs. 
CFC formulation (I 7) 
The clinical equivalence of efficacy and safety of the BDP 
Modulite@ was compared with that of BDP-CFC in 498 
clinically stable adult asthmatics treated by ICS delivered 
by MDI with or without a spacer and who required a 
daily dose of up to I500 ug of BDP equivalent. 
This was an equivalence multicentre, randomized 
(2 HFA, I CFC), double-blind parallel group study. After 
a l-week run-in period, patients were randomized to 
BDP Modulite@ or BDP-CFC. The treatment duration 
was 6 weeks. It was followed by an open-label safety study 
of 8 weeks treatment with BDP Modulite@ (Figure I). 
Both drugs were delivered with the addition of the 
jet@ spacer (Chiesi Farmaceutici). 
The treatment dosage was based on the replacement 
dose per dose, in term of BDP equivalent, of the previous 
treatment dosage with either BDP Modulite@ or BDP-CFC. 
Of the 498 patients included in the study, 473 were 
randomized and 443 were eligible for intent to treat 
analysis (293 patients in the group BDP Modulite@ and 
I50 patients in the group BDP-CFC). 
Patients demographics were similar in both groups in 
terms of age (44.8 f IS.4 years in the BDP Modulite” 
group and 45.8 f I5.4years in the BDP-CFC group), 
previous and concomitant treatments. However, there 
were more men (59.3%) in the BDP-CFC group than in 
the BDP Modulite@ group (47.8%). 
FEV, values were also similar in the two groups. 
The primary efficacy criterion recorded (PEFR) was 
recorded in the morning by an electronic flow meter 
(One Flow Meter). Morning PEFR was almost identical in 
both groups at randomization.There was an equivalence 
in morning PEFR between the two groups (Table I). 
Several secondary efficacy criteria were used: evening 
PEFR, PEFR variability, morning and evening FEV,, clinical 
symptoms, short-acting &-agonist rescue medications 
and the number of exacerbations defined as a PEFR 
variability > 20% for at least 2 consecutive days and/or &- 
agonist consumption z 3 double puffs per day for at least 
2 consecutive days and/or woken at night with asthma for 
at least 2 consecutive days. The clinical equivalence of 
BDP Modulite@ formulation was demonstrated for all 
parameters. In particular, the percentage of exacerbations 
was 12% in the BDP Modulite@ group and 10,7% in the 
BDP-CFC group. Diurnal PEFR variability after 6 weeks of 
treatment was under 10% in both groups. Moreover, 
46.9% in the BDP Modulite@ group and 47.3% patients in 
the BDP-CFC group required rescue salbutamol during 
the treatment period. 
The primary safety criterion was the adverse events 
spontaneously reported on the patient’s self assessment 
diary or detected at each visit in reply to the 
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investigator’s standard questions. Adverse events 
essentially affected the respiratory system and 
gastrointestinal tract with no difference between groups; 
82 adverse events were reported in the BDP-CFC group 
and I46 in the BDP Modulitd group. Only 8.8% of these 
events were scored as severe.The intensity and causality 
were similar in both groups. Only five patients dropped 
out from the study due to adverse events. 
Urinary cortisol was used as a secondary safety 
criterion.There was no statistical difference between the 
two groups for the urinary cortisol/creatinine ratio. 
Evaluation of laboratory parameters showed no 
difference between the two groups. 
A reduction in the frequency of adverse events and 
exacerbations of asthma was observed during the open- 
label treatment period with BDP Modulite@. 
In conclusion, analysis of morning PEFR, clinical and 
spirometric secondary parameters demonstrated the 
clinical equivalence of BDP Modulite@ and BDP-CFC 
formulations. The stability and similar diurnal PEFR 
variability suggests that BDP Modulite@ does not have 
any repercussion on bronchial hyperreactivity.The safety 
of BDP Modulite@ and BDP-CFC was similar, in 
particular in terms of urinary cortisol. 
The results of this study suggest that the non-extra 
fine BDP Modulite@ formulation makes possible a 
seamless transition from BDP-CFC with evident 
advantages for both patients and practitioners. 
2. Woodcock et al: Effects on lung 
function, symptoms and bronchial 
hyperreactivity of low-dose inhaled 
BDP given via HFA I34a or CFC 
propellant (I 8) 
The efficacy and safety of the BDP Modulite@ was 
compared with that of BDP-CFC (Becotidea, 
GlaxoSmithKline) in 172 asthmatic adults with stable 
mild persistent asthma (I) (FEV, > 70%, mean FEV, 
predicted > 90% in both groups). 
This was a single-centre, randomized, double-blind, 
double-dummy parallel group study.After a I -week run- 
in period, patients were randomized to receive a 6-week 
treatment with 200 ug of BDP Modulite” or BDP-CFC 
bid (Figure 2). 
In all, 84.9% of the patients in the BDP Modulite@ 
group and 8 I .4% of the patients in the BDP-CFC group 
were receiving ICS at the screening visit.The treatment 
was continued during the run-in period. 
Of the I72 patients included in the study, 164 
completed the study (85 patients in the group BDP 
Modulite@ and 79 patients in the group BDP-CFC). 
Patients demographics were similar in both groups in 
terms of age (39.0 f 13. I years in the BDP Modulite@ 
group and 37.0 f 13*0years in the BDP-CFC group), 
asthma severity, pulmonary function tests and previous 
and concomitant treatments. 
The primary efficacy criterion was the morning PEFR 
recorded daily by the Mini-Wright Flow Meter. Morning 
PEFR was almost identical in both groups at 
randomization. There was an equivalence in morning 
PEFR between the two groups (Figure 3). 
Several secondary efficacy criteria were used: evening 
PEFR, PEFR variability, FEV,, FVC and MEF,,, clinical 
symptoms, number of night-time awakenings, short- 
acting &-agonist rescue medications and the number of 
day-time and night-time exacerbations. In accordance 
with asthma of a mild severity, a slight improvement in 
lung function compared with baseline was seen for both 
groups, significantly for FEV, in BDP Modulite@ and 
MEF,, in both groups. The clinical equivalence of BDP 
Modulite@ and BDP-CFC formulations was demonstrated 
for all other parameters. 
A methacholine challenge test was completed at 
baseline and at the end of the 6-week treatment period in 
34 patients treated with BDP Modulite@ and 3 I patients 
treated with BDP-CFC.There were mild improvements in 
PD,, and PC,, methacholine in both groups with no 
significant difference between groups (Figure 4). 
The primary safety criterion was the adverse events 
detected at each visit in reply to the investigator’s 
standard questions; 22 drug-related adverse events were 
recorded in the BDP Modulite@ group and I9 in the 
BDP-CFC group. Most events were seasonal in nature or 
local effects due to the use of ICS. Only three patients in 
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the CFC-BDP group dropped out from the study due to 
adverse events. 
In conclusion, BDP Modulite@ seems to provide similar 
asthma control, compared with the same low daily dose 
of the active drug delivered via CFC.The safety of BDP 
Modulite@ and BDP-CFC was similar. 
The results of this study in mild-to-moderate 
persistent asthmatics suggest that the non-extra fine 
BDP Modulite@ formulation makes possible a seamless 
transition from BDP-CFC. 
Provocative concentration (PC&) 
Baseline .$fter 6 week\ 
BDP Modulir@’ 
BDP-CFC 
vs h1mYvv1 group\ 
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3.Vondra et &A new HFA I34a 
propellant in the administration of 
inhaled BDP via the Jet@ Spacer: 
controlled clinical trial vs. the 
conventional CFC (I 9) 
The efficacy and safety of the BDP Modulite@ 
administered via a spacer device (Jet@ spacer) was 
compared with that of BDP-CFC administered using the 
same device in I54 asthmatic adults with stable mild-to- 
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moderate persistent asthma (I) (FEV, ranging from 60 to 
90% of predicted values). 
This was a multicentre, randomized, double-blind, 
parallel group study. After a 2-week run-in period, 
patients were randomized to receive a l2-week 
treatment with 500 pg of BDP Modulite@ or BDP-CFC 
bid (Clenil@ Forte Jet@, Chiesi Farmaceutici) (Figure 5). 
For patients receiving ICS at study entry, the treatment 
was continued during the run-in period. 
Of the 154 patients included in the study, 147 
completed it (77 patients in the group BDP Modulite@ 
and 73 patients in the group BDP-CFC). 
Patients demographics were similar in both groups in 
terms of age (38.0 f 12. I years in the BDP Modulite@ 
group and 37.4 f 13.3 years in the BDP-CFC group), 
asthma severity, pulmonary function tests and previous 
and concomitant treatments. 
The primary efficacy criterion was the morning PEFR 
recorded daily by the Mini-Wright Flow Meter. Morning 
PEFR was almost identical in both groups at 
randomization. Morning PEFR increased from baseline to 
the final visit (Figure 6). There was an equivalence in 
morning PEFR between the two groups. 
Several secondary efficacy criteria were used: evening 
PEFR, PEFR variability, pre-bronchodilator FEV,, FVC, 
FEF,,-75% and MEF,,, clinical symptoms, number of night- 
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time awakenings, short-acting &-agonist rescue 
medications and the number of day-time and night-time 
exacerbations recorded on diary cards. Significant 
improvements over baseline were reported in both 
groups in terms of lung function (Figure 7) symptoms 
and use of rescue salbutamol.The clinical equivalence of 
BDP Modulite@ and BDP-CFC formulations was 
demonstrated for all other parameters. 
The primary safety criterion was the adverse events 
detected at each visit in reply to the investigator’s 
standard questions. Adverse events were reported in 
3 I % of patients in the BDP Modulite@ group and 32% in 
the BDP-CFC group. No drug-related serious adverse 
events were reported in either group. 
Morning serum cortisol (08.00 a.m. - IO.00 a.m.) was 
measured at the start and the end of the treatment 
period.Two patients went from normal to low levels in 
the two groups. One patient in the BDP-CFC group also 
had a low baseline value. The remaining patients had 
values within the normal range at both the baseline and 
end of treatment. 
In conclusion, BDP Modulite@ delivered using a spacer 
device (Jet? spacer) seems to provide similar asthma 
control, compared with the same high daily dose of the 
active drug delivered via CFC. The safety of BDP 
Modulite@ and BDP-CFC was similar. 
Morning PEFR (1 min-1) measured daily expressed 
as 2-weekly means (SD in bars) 
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The results of this study in mild-to-moderate 
persistent asthmatics suggest that the non-extra fine 
BDP Modulite@ formulation administered via a spacer 
device (Jet@ spacer) makes possible a seamless transition 
from BDP-CFC. 
4.Anderson et al: Equivalent efficacy and 
safety of a new HFA I34a formulation of 
BDP compared with the conventional 
CFC in adult asthmatics (20) 
The efficacy and safety of the BDP Modulite@ administered 
by MDI was compared with that of BDP-CFC 
administered by MDI (Becotide@, GlaxoSmithKline) in I I6 
asthmatic adults with stable mild, moderate-to-severe 
persistent asthma (I) (FEV, > 60% of predicted values). 
This was a multicentre, randomized, double-blind, 
double-dummy parallel group study.After a 2-week run- 
in period, patients were randomized to receive a l2- 
week treatment with 500 pg of BDP Modulite@ or 
BDP-CFC bid (Figure 8). 
All of the patients in the BDP Modulite@ and the 
BDP-CFC groups were receiving ICS (daily dose < I mg 
BDP equivalent) at the screening visit. Most patients 
were taking BDF? The treatment was continued during 
the run-in period. 
._ - -_-----+---_--- _~_~~ 
BDP Modulitee 2.54 * 14.5 2.72 t 1.06 i _-.---__I 
BDP-CFC 2.34 + 0.75 264LO.97 ~ ____. -.___ ____-__ 
Of the I I6 patients included in the study, 91 
completed the study (54 patients in the group BDP 
Modulite@ and 52 patients in the group BDP-CFC). 
Patients demographics were similar in both groups in 
terms of age (48.2 + 13.7 years in the BDP Modulite@ 
group and 46.7 + 15.9 years in the BDP-CFC group), 
asthma severity, pulmonary function tests and previous 
and concomitant treatments. 
The primary efficacy criterion was the morning PEFR 
recorded daily by the Mini-Wright Flow Meter. Morning 
PEFR was similar and non-significantly different in both 
groups at randomization. Morning PEFR slightly increased 
from baseline to the final visit.There was an equivalence 
in morning PEFR between the two groups. 
Several secondary efficacy criteria were used: 
evening PEFR, PEFR variability, pre-bronchodilator 
FEV,, FVC, FEF25_7s% and MEF,,, clinical symptoms, 
number of night-time awakenings, short-acting b2- 
agonist rescue medications and the number of day- 
time and night-time exacerbations recorded on diary 
cards. Values of pulmonary function texts were 
substantially unchanged during the entire study in both 
groups. Asthma control tended to improve during the 
study in both groups and there was no difference 
between groups in salbutamol rescue medication 
(Figure 9). The clinical equivalence of BDP Modulite@ 
FIGURE 8. Study design. 
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and BDP-CFC formulations was demonstrated for all 
parameters. 
The primary safety criterion was the adverse events 
detected at each visit in reply to the investigator’s 
standard questions. Adverse events were reported in 
57.6% of patients in the BDP Modulite@ group and 52.6% 
in the BDP-CFC group. No drug-related serious adverse 
events were reported in either group. Local side-effects 
were observed in I I patients in the BDP Modulite@ 
group and in I2 patients of the BDP-CFC group. 
Morning serum cortisol (08.00 a.m. - IO*00 a.m.) was 
measured at the start and the end of the treatment 
period. In the BDP Modulitd group, four patients went 
from normal to low levels, one patient had low levels at 
baseline and remained low, two patients went from low 
at baseline to normal levels at the end of the treatment 
period. In the BDP-CFC group, two patients went from 
normal baseline to low end of treatment level, one 
patient went from low to normal.The remaining patients 
had values within the normal range at both the baseline 
and end of treatment. 
In conclusion, BDP Modulite@ delivered using MDI 
seems to provide similar asthma control, compared with 
the same high daily dose of the active drug delivered via 
CFC. The safety of BDP Modulite@ and BDP-CFC was 
similar. 
The results of this study in mild, moderate-to-severe 
persistent asthmatics suggest that the non-ultra fine BDP 
Modulite@ formulation administered via MDI makes 
possible a seamless transition from BDP-CFC. 
5. Lee et crl:Assessment of efficacy and 
systemic safety of a new CFC-free 
formulation of inhaled BDP in asthmatic 
children (2 I) 
The efficacy and safety of the BDP Modulite@ 
administered by MDI was compared with that of BDP- 
CFC (Becotidea, GlaxoSmithKline) administered by MDI 
in 2 I8 asthmatic children (6- I6 years) with stable mild- 
to-moderate persistent asthma (I) (FEV, between 60% 
and 90% of predicted values). 
This was a multicentre, randomized, double-blind, 
double-dummy parallel group study.After a 2-week run- 
in period, patients were randomized to receive a l2- 
week treatment with 400 pg of BDP Modulite@ (50 ug 
unit dose), BDP Modulite@ (I 00 ug unit dose) or BDP- 
CFC (Becotide@, 50 p.g unit dose) daily (Figure IO). 
Due to practical difficulties encountered for a complete 
blinding of the trial (the use of four canisters would have 
been required), children assigned to the 100 ug dose 
strength were treated on an open-label design. Most of 
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the patients were already treated by KS, mainly BDP, at a 
daily dose of up to 400 pg daily (95.8% in the BDP 
Modulite@ 50 pg group, 9 I % in the BDP Modulite@ IO0 pg 
group and 84.5% in the BDP-CFC group).The treatment 
was continued during the run-in period. 
Of the 218 patients included in the study, 207 
completed the study (71 patients in the BDP Modulite@ 
50 pg group, 65 patients in the BDP Modulite@ IO0 yg 
group and 7 I patients in the BDP-CFC group for the ITT 
analysis). However, for the per protocol (PP) analysis, 
there were 63 patients in the BDP Modulite@ 5Opg 
group, 58 patients in the BDP Modulite@ IO0 pg group 
and 63 patients in the BDP-CFC group. 
Patients demographics were similar in both groups in 
terms of age (IO.8 f 3.0 years in the BDP Modulite@ 
50 pg group, I I.4 f 2.6 years in the BDP Modulite@ 
100 pg group and IO.8 + 2.8 years in the BDP-CFC 
group), asthma severity, pulmonary function tests and 
previous and concomitant treatments. 
The primary efficacy criterion was the morning PEFR 
recorded daily by the Mini-Wright Flow Meter. Morning 
PEFR was similar and non-significantly different in the 
three groups at randomization. Morning PEFR 
significantly increased from baseline after the 6th week 
of treatment in the three groups (P S: O.O5).There was an 
equivalence in morning PEFR between the two groups 
(Figure I I). 
Several secondary efficacy criteria were used: evening 
PEFR, PEFR variability, pre-bronchodilator FEV,, FVC, 
FEF,,-75% FEF,,, and MEF,,, clinical symptoms, number of 
night-time awakenings, short-acting &-agonist rescue 
medications and the number of day-time and night-time 
exacerbations recorded on diary cards. 
A statistically significant (P < 0.05) increase over 
baseline of FEV, was reported at each visit except at the 
final visit in the BDP-CFC group.The results of the other 
pulmonary function tests showed statistically significant 
improvements over baseline for BDP Modulitea. BDP- 
CFC appeared to be significantly less effective for some 
points (Table 2). 
Superiority of BDP Modulite@ over BDP-CFC was 
observed for some parameters. 
Symptom scores significantly decreased at all times in 
the three groups except for BDP Modulite@ 100 c(g in 
the final 2 weeks (Table 3). 
A significant decrease of salbutamol rescue medication 
occurred at all times in the BDP-CFC group and at 
weeks 7-8 in the BDP Modulite@ 100 pg group. 
The clinical equivalence of BDP Modulite@ 50 pg, BDP 
Modulite@ 100 pg and BDP-CFC formulations was 
demonstrated for most but not all parameters. However, 
differences were small albeit significant, and were not 
always found for the same formulation. Since patients in 
the BDP-CFC group tended to receive less salbutamol 
rescue medication, and these patients had a poorer 
control of the disease, it is possible that the differences 
seen were related to the amount of rescue medication, 
suggesting that there is an overall equivalence for the 
three formulations. 
The primary safety criterion was the adverse events 
detected at each visit in reply to the investigator’s 
standard questions. Drug-related adverse events were 
reported in I I. I % patients in the BDP Modulite@ 50 pg 
group, 17.9% patients in the BDP Modulite@ 100 pg 
group and 12.7% patients in the BDP-CFC group. The 
most common adverse events were respiratory tract 
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infections. Two other patients of the BDP Modulite@ group, two patients in the BDP Modulite@ 100 pg 
100 yg group reported episodes of oral mycosis. No group and two patients in the BDP-CFC group 
drug-related serious adverse events were reported in discontinued the study medication due to adverse 
either group. Four patients in the BDP Modulite@ 50 ug events. 
Morning serum cortisol (08.00 a.m. - IO.00 a.m.) was 
measured at the start and the end of the treatment 
period in 25 patients in the BDP Modulite@ 50 pg group, 
33 patients in the BDP Modulite@ IO0 pg group and 35 
patients in the BDP-UC group. Only two patients in the 
BDP Modulite@ 100 pg group had final values slightly 
below the lower limit of the normal range. On the other 
hand, an increase in the mean values was reported in the 
three patients groups. 
In conclusion, BDP Modulite@ delivered using MDI 
seems to provide similar asthma control, compared with 
the same daily dose of the active drug delivered via CFC. 
The safety of BDP Modulite” and BDP-CFC was similar. 
The results of this study in mild, moderate-to-severe 
persistent asthmatic children suggest that the non-extra 
fine BDP Modulite@ formulation administered via MDI 
makes possible a seamless transition from BDP-CFC. 
CONCLUSIONS 
The key objectives of the clinical development 
programme designed for BDP Modulite@ were: 
I. to confirm that the similar in vitro performance of BDP 
Modulite@ and BDP-CFC MDls translates into 
equivalent therapeutic efficacy, 
2. to assess the local and systemic safety of the BDP 
Modulite@ vs. BDP-CFC in asthma patients after 
prolonged administration, 
3. to provide evidence that the risk/benefit ratio of the 
new BDP Modulite@ formulation is comparable with 
currently available BDP-CFC products. 
Studies carried out with the BDP Modulite@ have 
been performed according to the recommendations of 
the European Guidelines for the phase-out of CFCs in 
the MDls. 
The following conclusions can be made: 
l.Three pivotal clinical studies (18,20,21) have been 
undertaken to evaluate the performance of the BDP 
Modulite@ 50 pg, 100 pg and 250 pg inhalers. One of 
the studies (21) was undertaken in a paediatric 
population of mild, moderate and severe asthmatics, 
the others were undertaken in mild or mild, moderate 
and severe asthmatic adults. A range of doses from 
200 pg bid to 500 bg bid has been evaluated against 
BDP-CFC comparators. 
2.Two supporting studies (I 7,19) have been performed 
in adults using the Jet@ spacer actuator. 
3. The primary efficacy variable in all studies was 
morning PEFR. Secondary variables included other 
lung function parameters, symptom scores and 
salbutamol use. 
4.All studies demonstrated similarity for the BDP 
Modulite@ products relative to the BDP-CFC 
products. The confidence intervals for this analysis 
were well within the equivalence hypothesis. 
5. There were no apparent differences in the occurrence 
of general adverse events in patients treated with BDP 
Modulite@ inhalers as opposed to BDP-CFC inhalers. 
The rates of occurrence of local adverse events 
(oropharyngeal and respiratory tract) were also 
similar for both types of treatment. 
6. Morning serum cortisol values were measured in three 
studies. No significant decreases in the mean value 
were seen in any of the treatment groups. 
7. A subset of adult patients treated with 200 pg bid was 
challenged with methacholine.There was no difference 
in the bronchial hyper-reactivity of patients treated 
with BDP-CFC and BDP Modulite@ products. 
These studies confirm that BDP Modulite@ produces 
solution formulations of BDP-HFA l34a in pressurized 
MDls that are equivalent in terms of efficacy, safety and 
dose per actuation performance to the currently 
marketed BDP-CFC containing products.This new non- 
extra fine HFA l34a formulation allows a seamless 
transition to CFC-free BDP in order to minimize 
difficulties to both prescribers and patients. 
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